Financials (USD)
Sales 2024 * | 85.62M | Sales 2025 * | 79.71M | Capitalization | 323M |
---|---|---|---|---|---|
Net income 2024 * | -165M | Net income 2025 * | -167M | EV / Sales 2024 * | 2.43 x |
Net cash position 2024 * | 115M | Net cash position 2025 * | 281M | EV / Sales 2025 * | 0.52 x |
P/E ratio 2024 * |
-2.05
x | P/E ratio 2025 * |
-2.58
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.63% |
Latest transcript on Nektar Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 06-12-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 23-04-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 09-12-31 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 00-07-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+29.37% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.34% | 240B | |
+8.77% | 208B | |
-7.73% | 200B | |
+7.68% | 166B |